Strategic Collaboration Agreement Between Isis Pharmaceuticals, Inc., And AstraZeneca ABStrategic Collaboration Agreement • June 10th, 2016 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • New York
This STRATEGIC COLLABORATION AGREEMENT (the “Agreement”) is entered into as of the 31st day of July, 2015 (the “Execution Date”) by and between Isis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and AstraZeneca AB, a company incorporated in Sweden under no. 556011-7482 with its registered office at SE-151 85 Södertälje, Sweden (“AstraZeneca”). AstraZeneca and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices, exhibits and schedules are a part of this Agreement.
AMENDMENT #6 TO RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • June 10th, 2016 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations
This AMENDMENT #6 TO THE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment No. 6”) is entered into and made effective as of the 2nd day of September, 2015 (the “Amendment No. 6 Date”) by and between Isis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford, London TW8 9GS, United Kingdom (“GGL”), and Glaxosmithkline intellectual property development limited, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford London TW8 9GS, United Kingdom (“GSK IPDL”). GGL and GSK IPDL are referred to together as (“GSK”). Isis and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
